What is Mounjaro (tirzepatide)?
Mounjaro (tirzepatide) is a GLP-1 receptor agonist originally developed for type 2 diabetes. It is now approved by the NHS for weight management due to its significant weight loss effects. It works by mimicking natural hormones to suppress appetite and slow gastric emptying, helping patients reduce calorie intake and achieve weight loss.
Who is eligible for free weight loss jabs?
According to the latest NHS guidance, you may qualify for free Mounjaro on the public health system if you meet these criteria:
- BMI requirements: Typically a BMI ≥30 kg/m² (obese class). For those with obesity-related complications like hypertension, type 2 diabetes, or sleep apnea, the threshold may be lowered to BMI ≥27 kg/m².
- Age: Currently approved for adults aged 18-65.
- Prior weight loss attempts: You must have tried lifestyle interventions (diet and exercise) for at least 6 months with insufficient results.
- Exclusions: People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2) cannot use Mounjaro.
How to calculate your BMI
BMI = weight (kg) ÷ height (m)². For example, if you weigh 80 kg and are 1.7 m tall: BMI=80÷(1.7×1.7)=27.7. Use an online calculator or ask your GP for help.
How to get prescribed
If you think you qualify, book an appointment with your GP for a full assessment. The doctor will review your medical history, measure your height and weight, assess risk for complications, and decide whether to prescribe. NHS referrals typically go through specialist weight management services; not all clinics offer it directly.
Risks and side effects
Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. Mounjaro may also increase the risk of pancreatitis, gallbladder disease, and severe hypoglycemia (especially if combined with other diabetes medications). Discuss the benefits and risks thoroughly with your doctor.